Aldo Carrascoso

Aldo is a visionary entrepreneur and technology leader known for his ability to innovate and disrupt traditional industries. As the Co-Founder and CEO of InterVenn Biosciences, he led the company in creating a first-of-its-kind glycoproteomic biomarker interrogation platform called GlycoVisionTM using AI and machine learning, which improved the diagnosis and treatment of various diseases through liquid biopsies. This platform was based on the decades-long work of his co-founders, Nobel Laureate Dr. Carolyn Bertozzi from Stanford (glycobiology) and renowned scientist Dr. Carlito Lebrilla from UC Davis (glycoproteomics).

Under Aldo's leadership, InterVenn revolutionized the field of precision medicine by being the first to scalably unlock the glycoproteome, which has enabled the accurate and early detection of diseases such as cancer and autoimmune diseases. Additionally, the company's cutting-edge technology has facilitated the identification of new biomarkers and drug targets, paving the way for the development of more effective treatments and diagnostics, such as DawnTM for Immunotherapy, GloriTM For Ovarian Cancer, and GlycoKnowTM Colorectal.

Prior to InterVenn, he founded and was CTO at Veem (2013), a global cross-border payment processing company and blockchain pioneer, and Jukin Media (2009), one of the world's largest UGC licensing platforms that has over half a trillion views. Aldo has a proven track record of success as an entrepreneur, having founded companies that have generated significant value for investors (>$1B) and improved people's lives. He is also an active angel investor and holds an MBA from Babson and a BS from Ateneo De Manila University. Aldo is widely respected for his deep understanding of transformative technologies such as AI, data science, blockchain, and cloud computing.